Tenofovir–disoproxil–fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection-Reference-Cited by-同舟云学术

Tenofovir–disoproxil–fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection

Published:2020-11-19 Issue:2 Volume:56 Page:168-180
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Suzuki Kazuharu, ,Suda Goki^ORCID,Yamamoto Yoshiya,Furuya Ken,Baba Masaru,Nakamura Akinobu,Miyoshi Hideaki,Kimura Megumi,Maehara Osamu,Yamada Ren,Kitagataya Takashi,Yamamoto Koji,Shigesawa Taku,Nakamura Akihisa,Ohara Masatsugu,Kawagishi Naoki,Nakai Masato,Sho Takuya,Natsuizaka Mitsuteru,Morikawa Kenichi,Ogawa Koji,Ohnishi Shunsuke,Sakamoto Naoya

Funder

Japan Agency for Medical Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-020-01750-3.pdf

Reference51 articles.

1. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053–63.

2. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–45.

3. Walter SR, Thein HH, Gidding HF, et al. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol. 2011;26:1757–64.